Skip to Main Content

As drug makers struggle to get medicines out the door, executives involved in the process say that it’s taking more time than ever to get mid-stage and late-stage clinical trials up and running.

The average amount of time from identifying useful study sites to launching a Phase 2 or Phase 3 trial now takes 31.4 weeks, or nearly eight months, which is one month longer than a decade ago, according to a survey conducted by the Tufts Center for the Study of Drug Development.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.